CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report

Julia R. Naso; Sarah M. Jenkins; Julie A. Vrana; Justin W. Koepplin; Kenneth R. Olivier; Stephen Cassivi; Julian R Molina; Anja C. Roden

doi:10.1016/j.jtocrr.2025.100803

CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report

Julia R. Naso, Sarah M. Jenkins, Julie A. Vrana, Justin W. Koepplin, Kenneth R. Olivier, Stephen Cassivi, Julian R Molina, Anja C. Roden

Research output: Contribution to journal › Article › peer-review

Abstract

Thymic carcinomas are a heterogeneous group of potentially aggressive malignancies. We aimed to determine the prognostic significance of CD5, CD117, EZH2, POU2F3, BAP1, and MTAP immunohistochemical staining in thymic carcinomas. Immunohistochemistry was performed on 36 thymic carcinomas from patients with retrospectively collected survival data. Thirteen cases (36%) had CD5 staining in 50% or more tumor cells, considered positive staining. Positive CD5 immunohistochemical staining was significantly associated with longer overall survival (hazard ratio = 0.18, 95% confidence interval: 0.03–0.63, p = 0.005). Three-year overall survival was 48% (95% confidence interval: 27%–70%) for CD5 negative cases, and 100% for CD5 positive cases. Positive CD5 staining remained significantly associated with overall survival after adjusting for neoadjuvant treatment, M-stage, or incomplete resection (p = 0.01). The remaining immunohistochemical markers were not significantly associated with overall survival. Our study supports the notion that CD5 immunohistochemistry may have utility as a novel prognostic marker for thymic carcinoma.

Original language	English (US)
Article number	100803
Journal	JTO Clinical and Research Reports
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/j.jtocrr.2025.100803
State	Published - May 2025

Keywords

CD5
Immunohistochemistry
Pathology
Prognosis
Survival
Thymic carcinoma

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtocrr.2025.100803

Cite this

@article{60a485cc62b84a749c986551e9645f62,

title = "CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report",

abstract = "Thymic carcinomas are a heterogeneous group of potentially aggressive malignancies. We aimed to determine the prognostic significance of CD5, CD117, EZH2, POU2F3, BAP1, and MTAP immunohistochemical staining in thymic carcinomas. Immunohistochemistry was performed on 36 thymic carcinomas from patients with retrospectively collected survival data. Thirteen cases (36%) had CD5 staining in 50% or more tumor cells, considered positive staining. Positive CD5 immunohistochemical staining was significantly associated with longer overall survival (hazard ratio = 0.18, 95% confidence interval: 0.03–0.63, p = 0.005). Three-year overall survival was 48% (95% confidence interval: 27%–70%) for CD5 negative cases, and 100% for CD5 positive cases. Positive CD5 staining remained significantly associated with overall survival after adjusting for neoadjuvant treatment, M-stage, or incomplete resection (p = 0.01). The remaining immunohistochemical markers were not significantly associated with overall survival. Our study supports the notion that CD5 immunohistochemistry may have utility as a novel prognostic marker for thymic carcinoma.",

keywords = "CD5, Immunohistochemistry, Pathology, Prognosis, Survival, Thymic carcinoma",

author = "Naso, {Julia R.} and Jenkins, {Sarah M.} and Vrana, {Julie A.} and Koepplin, {Justin W.} and Olivier, {Kenneth R.} and Stephen Cassivi and Molina, {Julian R} and Roden, {Anja C.}",

note = "Publisher Copyright: {\textcopyright} 2025 The Authors",

year = "2025",

month = may,

doi = "10.1016/j.jtocrr.2025.100803",

language = "English (US)",

volume = "6",

journal = "JTO Clinical and Research Reports",

issn = "2666-3643",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma

T2 - A Brief Report

AU - Naso, Julia R.

AU - Jenkins, Sarah M.

AU - Vrana, Julie A.

AU - Koepplin, Justin W.

AU - Olivier, Kenneth R.

AU - Cassivi, Stephen

AU - Molina, Julian R

AU - Roden, Anja C.

PY - 2025/5

Y1 - 2025/5

N2 - Thymic carcinomas are a heterogeneous group of potentially aggressive malignancies. We aimed to determine the prognostic significance of CD5, CD117, EZH2, POU2F3, BAP1, and MTAP immunohistochemical staining in thymic carcinomas. Immunohistochemistry was performed on 36 thymic carcinomas from patients with retrospectively collected survival data. Thirteen cases (36%) had CD5 staining in 50% or more tumor cells, considered positive staining. Positive CD5 immunohistochemical staining was significantly associated with longer overall survival (hazard ratio = 0.18, 95% confidence interval: 0.03–0.63, p = 0.005). Three-year overall survival was 48% (95% confidence interval: 27%–70%) for CD5 negative cases, and 100% for CD5 positive cases. Positive CD5 staining remained significantly associated with overall survival after adjusting for neoadjuvant treatment, M-stage, or incomplete resection (p = 0.01). The remaining immunohistochemical markers were not significantly associated with overall survival. Our study supports the notion that CD5 immunohistochemistry may have utility as a novel prognostic marker for thymic carcinoma.

AB - Thymic carcinomas are a heterogeneous group of potentially aggressive malignancies. We aimed to determine the prognostic significance of CD5, CD117, EZH2, POU2F3, BAP1, and MTAP immunohistochemical staining in thymic carcinomas. Immunohistochemistry was performed on 36 thymic carcinomas from patients with retrospectively collected survival data. Thirteen cases (36%) had CD5 staining in 50% or more tumor cells, considered positive staining. Positive CD5 immunohistochemical staining was significantly associated with longer overall survival (hazard ratio = 0.18, 95% confidence interval: 0.03–0.63, p = 0.005). Three-year overall survival was 48% (95% confidence interval: 27%–70%) for CD5 negative cases, and 100% for CD5 positive cases. Positive CD5 staining remained significantly associated with overall survival after adjusting for neoadjuvant treatment, M-stage, or incomplete resection (p = 0.01). The remaining immunohistochemical markers were not significantly associated with overall survival. Our study supports the notion that CD5 immunohistochemistry may have utility as a novel prognostic marker for thymic carcinoma.

KW - CD5

KW - Immunohistochemistry

KW - Pathology

KW - Prognosis

KW - Survival

KW - Thymic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=105001834424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=105001834424&partnerID=8YFLogxK

U2 - 10.1016/j.jtocrr.2025.100803

DO - 10.1016/j.jtocrr.2025.100803

M3 - Article

AN - SCOPUS:105001834424

SN - 2666-3643

VL - 6

JO - JTO Clinical and Research Reports

JF - JTO Clinical and Research Reports

IS - 5

M1 - 100803

ER -

CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this